Last reviewed · How we verify
Lomotil (DIPHENOXYLATE)
Lomotil (DIPHENOXYLATE) is a small molecule antidiarrheal medication originally developed by GD SEARLE LLC and currently owned by the same company. It targets the mu-type opioid receptor to treat diarrhea. Lomotil was FDA approved in 1960 and is used to treat various types of diarrhea. The commercial status of Lomotil is not explicitly stated, but it is likely to be a branded medication. Key safety considerations include potential dependence and abuse.
At a glance
| Generic name | DIPHENOXYLATE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Antidiarrheal |
| Target | Mu-type opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1960 |
Approved indications
- Diarrhea
Common side effects
- Nausea
- Vomiting
- Anorexia
- Abdominal discomfort
- Toxic megacolon
- Paralytic ileus
- Pancreatitis
- Urinary retention
- Hyperthermia
- Tachycardia
- Flushing
- Dryness of the skin and mucous membranes
Drug interactions
- rasagiline
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
- Premedication for Less Invasive Surfactant Administration Study (PRELISA) (PHASE4)
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial (NA)
- Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PHASE4)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1,PHASE2)
- The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lomotil CI brief — competitive landscape report
- Lomotil updates RSS · CI watch RSS
- Pfizer portfolio CI